title: Conventional and new diagnostic applications of a two-site immunochemiluminometric assay for parathyroid hormone.
abstract: This investigation was carried out to evaluate the clinical utility and diagnostic value of serum intact PTH measurement using a recently introduced immunochemiluminometric assay (ICMA). Studies were carried out in 42 normal subjects, 24 patients with primary hyperparathyroidism, 21 patients on chronic maintenance hemodialysis, 8 patients with postsurgical hypoparathyroidism, 7 patients with cancer hypercalcemia and 6 patients with osteomalacia. A good correlation was found in normal subjects between serum ICMA PTH levels and both intact PTH measured by a two-site immunoradiometric assay (n = 42, r = 0.67, p less than 0.001) and a widely used midmolecule radioimmunoassay (n = 21, r = 0.78; p less than 0.001). Similar good correlations were found in primary hyperparathyroidism patients (IC-MA vs immunoradiometric assay r = 0.74; p less than 0.001; ICMA vs midmolecule assay r = 0.77; p less than 0.001). As far as the hypercalcemic conditions were concerned, in 5 patients with mild primary hyperparathyroidism, ICMA PTH levels were in the upper range of those found in normal subjects, even though they were inappropriately high in respect to serum calcium values. However, serum ICMA PTH levels were clearly suppressed or undetectable in the majority of patients with cancer hypercalcemia or postsurgical hypoparathyroidism. Following calcium and EDTA infusions in patients with primary hyperparathyroidism, the behaviour of ICMA PTH levels in general parallelled that of immunoradiometric PTH assay, thus indirectly suggesting the ability of the method to measure the intact molecule.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di II Clinica Medica, Medicina Interna, Università degli Studi di Roma, La Sapienza, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Minisola
authors.forename: L
authors.initials: L
authors.lastname: Scarnecchia
authors.forename: E
authors.initials: E
authors.lastname: Romagnoli
authors.forename: V
authors.initials: V
authors.lastname: Carnevale
authors.forename: M T
authors.initials: MT
authors.lastname: Pacitti
authors.forename: A
authors.initials: A
authors.lastname: Scarda
authors.forename: R
authors.initials: R
authors.lastname: Rosso
authors.forename: G F
authors.initials: GF
authors.lastname: Mazzuoli
mesh_terms: D000236:Adenoma / Q000097:blood / Q000150:complications; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D002118:Calcium / Q000097:blood; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D006961:Hyperparathyroidism / Q000097:blood* / Q000175:diagnosis; D007011:Hypoparathyroidism / Q000097:blood* / Q000175:diagnosis; D007158:Immunologic Techniques; D015592:Immunoradiometric Assay; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000175:diagnosis; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D010281:Parathyroid Hormone / Q000097:blood*; D010282:Parathyroid Neoplasms / Q000097:blood / Q000150:complications; D011183:Postoperative Complications; D011863:Radioimmunoassay
chemical_list: D010281:Parathyroid Hormone; D002118:Calcium